Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, announced that CEO Herriot Tabuteau and the management team will ring the NASDAQ opening bell on July 21, 2025. The ceremony coincides with their Frontiers in Brain Health R&D Day event.
The event highlights Axsome's progress in developing late-stage CNS product candidates and celebrates the recent U.S. launch of SYMBRAVO®. The company aims to transform clinical practice in brain health through its portfolio of marketed medicines and investigational treatments for CNS conditions. The bell ringing ceremony will be held at the Nasdaq MarketSite in Times Square, New York, starting at 9:20 a.m. ET.
Axsome Therapeutics (NASDAQ:AXSM), un'azienda biofarmaceutica specializzata in disturbi del sistema nervoso centrale (SNC), ha annunciato che l'amministratore delegato Herriot Tabuteau e il team di gestione suoneranno la campanella di apertura del NASDAQ il 21 luglio 2025. La cerimonia coincide con l'evento Frontiers in Brain Health R&D Day.
L'evento mette in evidenza i progressi di Axsome nello sviluppo di candidati farmaci per il SNC in fase avanzata e celebra il recente lancio negli Stati Uniti di SYMBRAVO®. L'azienda punta a trasformare la pratica clinica nella salute cerebrale attraverso il suo portafoglio di farmaci commercializzati e trattamenti sperimentali per condizioni del SNC. La cerimonia della campanella si terrà al Nasdaq MarketSite in Times Square, New York, a partire dalle 9:20 a.m. ET.
Axsome Therapeutics (NASDAQ:AXSM), una compañía biofarmacéutica centrada en trastornos del sistema nervioso central (SNC), anunció que el CEO Herriot Tabuteau y el equipo directivo tocarán la campana de apertura del NASDAQ el 21 de julio de 2025. La ceremonia coincide con su evento Frontiers in Brain Health R&D Day.
El evento destaca los avances de Axsome en el desarrollo de candidatos a productos para el SNC en etapas avanzadas y celebra el reciente lanzamiento en EE.UU. de SYMBRAVO®. La compañía busca transformar la práctica clínica en salud cerebral mediante su portafolio de medicamentos comercializados y tratamientos en investigación para condiciones del SNC. La ceremonia de campana se realizará en el Nasdaq MarketSite en Times Square, Nueva York, a partir de las 9:20 a.m. ET.
Axsome Therapeutics (NASDAQ:AXSM)는 중추신경계(CNS) 질환에 중점을 둔 생명공학 제약회사로, CEO 헤리엇 타뷰토(Herriot Tabuteau)와 경영진이 2025년 7월 21일 나스닥 개장 종을 울릴 예정이라고 발표했습니다. 이 행사는 Frontiers in Brain Health R&D Day 행사와 함께 진행됩니다.
이번 행사는 Axsome이 후기 단계 CNS 제품 후보 개발에서 이룬 진전을 강조하며, 최근 미국에서 출시된 SYMBRAVO®를 기념합니다. 회사는 CNS 질환을 위한 상용 의약품과 임상 시험 중인 치료제 포트폴리오를 통해 뇌 건강 임상 실무를 혁신하는 것을 목표로 합니다. 종 울림 행사는 뉴욕 타임스퀘어 Nasdaq MarketSite에서 동부시간 기준 오전 9시 20분에 시작됩니다.
Axsome Therapeutics (NASDAQ:AXSM), une société biopharmaceutique spécialisée dans les troubles du système nerveux central (SNC), a annoncé que le PDG Herriot Tabuteau et l'équipe de direction sonneront la cloche d'ouverture du NASDAQ le 21 juillet 2025. La cérémonie coïncide avec leur événement Frontiers in Brain Health R&D Day.
L'événement met en lumière les progrès d'Axsome dans le développement de candidats médicaments pour le SNC en phase avancée et célèbre le lancement récent aux États-Unis de SYMBRAVO®. La société vise à transformer la pratique clinique en santé cérébrale grâce à son portefeuille de médicaments commercialisés et de traitements en cours d'investigation pour les affections du SNC. La cérémonie de la cloche aura lieu au Nasdaq MarketSite à Times Square, New York, à partir de 9h20 ET.
Axsome Therapeutics (NASDAQ:AXSM), ein biopharmazeutisches Unternehmen mit Fokus auf Erkrankungen des zentralen Nervensystems (ZNS), gab bekannt, dass CEO Herriot Tabuteau und das Managementteam am 21. Juli 2025 die NASDAQ-Eröffnungsglocke läuten werden. Die Zeremonie findet im Rahmen ihres Frontiers in Brain Health R&D Day statt.
Die Veranstaltung hebt Axsome's Fortschritte bei der Entwicklung von Spätphasen-ZNS-Produktkandidaten hervor und feiert die kürzliche Markteinführung von SYMBRAVO® in den USA. Das Unternehmen verfolgt das Ziel, die klinische Praxis im Bereich Gehirngesundheit durch sein Portfolio vermarkteter Medikamente und experimenteller Behandlungen für ZNS-Erkrankungen zu verändern. Die Glockenzeremonie findet im Nasdaq MarketSite in Times Square, New York, ab 9:20 Uhr ET statt.
- None.
- None.
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today.
Herriot Tabuteau, MD, Chief Executive Officer of Axsome said, “We are thrilled to ring NASDAQ’s opening bell in connection with our Frontiers in Brain Health R&D Day today, showcasing our pioneering work across our pipeline of innovative, late-stage CNS product candidates, and commemorating the recent availability of SYMBRAVO® by prescription in the U.S. With our growing portfolio of differentiated on-market medicines, and our pipeline of potentially transformative investigational medicines, Axsome is defining the future of clinical practice in brain health to improve the lives of the millions of patients living with serious and difficult-to-treat CNS conditions.”
The opening bell ceremony will take place at the Nasdaq MarketSite located in Times Square, New York, NY. The live ceremonies will begin at 9:20 a.m. Eastern Time and can be viewed at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Nasdaq MarketSite Media Contact:
Sophia Weiss
(646) 483-6960
Sophia.weiss@nasdaq.com
FAQ
When is Axsome Therapeutics (AXSM) ringing the NASDAQ opening bell?
Why is Axsome Therapeutics (AXSM) ringing the NASDAQ bell?
What is SYMBRAVO by Axsome Therapeutics (AXSM)?
Where can I watch Axsome Therapeutics' NASDAQ bell ringing ceremony?
What type of medications does Axsome Therapeutics (AXSM) develop?
